Tardive dyskinesia is a rare involuntary, often mute, motor neural disease caused by the excessive use of dopamine antagonist drugs that are usually prescribed to treat some psychiatric or gastrointestinal disorders. Long term use of such drugs can produce severe biochemical changes in the brain's reward system, the part of the brain which is involved in coordinating behavior with the actions of the body. The main causes that some of those who take such drugs might acquire tardive dyskinesia is unknown, but the main reasons that others don't is still unknown.
Market Dynamics
High prevalence of neurological diseases is expected to propel growth of the tardive dyskinesia drugs market. For instance, according to the World Health Organization (WHO), the percentage of total disability-adjusted life years (DALYs) of epilepsy is expected to account for 0.5% while of cerebrovascular diseases for 3.6%. Moreover, percentage of total DALYs of cerebrovascular disease is projected to reach 3.9%, while that of epilepsy is expected to remain more or less constant by 2030. Moreover, high prevalence of tardive dyskinesia is also expected to aid in growth of the market. The average prevalence of tardive dyskinesia is estimated to be at least 20% of all patients who were treated with first-generation neuroleptics.
Increasing geriatric population is expected to offer lucrative growth opportunities for players in the tardive dyskinesia drugs market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Moreover, increasing sales of tardive dyskinesia drugs is also expected to aid in growth of the market. For instance, in January 2021, Neurocrine Biosciences, Inc. reported that full-year 2020 total INGREZZA (INGREZZA is a selective vesicular monoamine transporter 2 inhibitor indicated for the treatment of adults with tardive dyskinesia) prescriptions grew 32% to approximately 175,700 versus 2019 total prescriptions of approximately 132,700.
Competitive Analysis
Major players operating in the tardive dyskinesia drugs market include, Valeant Pharmaceuticals, Neurocrine Biosciences, and Teva Pharmaceutical Industries.
Major players operating in the tardive dyskinesia drugs market are focused on adopting various strategies to enhance their market share. For instance, in September 2020, Neurocrine Biosciences, Inc. announced to present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia and Parkinson's disease at the virtual scientific meetings, 2020 Psych Congress and the MDS Virtual Congress 2020.
In-depth Report on Tardive Dyskinesia Drugs Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/ongoing-insight/tardive-dyskinesia-drugs-market-218
No comments:
Post a Comment